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The Majority of Generalized Pustular Psoriasis without
Psoriasis Vulgaris Is Caused by Deficiency of
Interleukin-36 Receptor Antagonist
Kazumitsu Sugiura1, Akemi Takemoto2, Michiya Yamaguchi2, Hidetoshi Takahashi3, Yukiko Shoda4,
Teruyuki Mitsuma5, Kenshiro Tsuda6, Emi Nishida7, Yaei Togawa8, Kimiko Nakajima9, Akihiro Sakakibara10,
Shigeo Kawachi11, Makoto Shimizu12, Yasutomo Ito13, Takuya Takeichi1,14, Michihiro Kono1,
Yasushi Ogawa1, Yoshinao Muro1, Akemi Ishida-Yamamoto3, Shigetoshi Sano9, Hiroyuki Matsue8,
Akimichi Morita7, Hitoshi Mizutani6, Hajime Iizuka3, Masahiko Muto2 and Masashi Akiyama1
Generalized pustular psoriasis (GPP) is a rare inflammatory skin disease that can be life-threatening. Recently, it
has been reported that familial GPP is caused by homozygous or compound heterozygous mutations of IL36RN.
However, the majority of GPP cases are sporadic and it is controversial whether IL36RNmutations are a causative/
predisposing factor for sporadic GPP. We searched for IL36RN mutations in two groups of GPP patients in the
Japanese population in this study: GPP without psoriasis vulgaris (PV), and GPP with PV. Eleven cases of GPP
without PV (GPP alone) and 20 cases of GPP accompanied by PV (GPP with PV) were analyzed. Surprisingly, 9 out
of 11 cases of GPP alone had homozygous or compound heterozygous mutations in IL36RN. In contrast, only 2 of
20 cases of GPP with PV had compound heterozygous mutations in IL36RN. The two cases of GPP with PV who
had compound heterozygous mutations in IL36RN are siblings, and both cases had PV-susceptible HLA-A*0206.
We determined that GPP alone is a distinct subtype of GPP and is etiologically distinguished from GPP with PV,
and that the majority of GPP alone is caused by deficiency of the interleukin-36 receptor antagonist due to IL36RN
mutations.
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INTRODUCTION
Generalized pustular psoriasis (GPP) is a rare inflammatory
skin disease that is often associated with fever and systemic
involvement and is sometimes fatal. The skin manifestations of
GPP are episodic sterile pustules on an erythematous back-
ground over wide areas of the body. A number of factors,
including pregnancy, infection, and exposure to drugs, may
trigger GPP. GPP often presents in patients with existing
or prior psoriasis vulgaris (PV). However, cases of GPP have
been known to arise without a history of PV. Although GPP
is a variant form of psoriasis, the remarkable clinical and
histological differences suggest that it might be a disease
with a distinct etiology. In addition, there has long been
controversy over whether GPP alone and GPP accompanied
by PV are distinct subtypes that are etiologically different from
each other.
The pathogenesis of GPP is unclear, except for familial GPP
or a few cases of sporadic GPP, whose cause was found to be
homozygous or compound heterozygous mutations in the
gene IL36RN, also known as IL1F5, encoding the interleukin-
36 receptor antagonist (IL36RN) (Marrakchi et al., 2011;
Onoufriadis et al., 2011; Sugiura et al., 2012; Farooq et al.,
2013; Setta-Kaffetzi et al., 2013). This genetic disorder is
also called deficiency of interleukin-36 receptor antagonist
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(DITRA) (Marrakchi et al., 2011; Cowen and Goldbach-
Mansky, 2012). We recently reported the first case of DITRA
in an Asian population (Sugiura et al., 2012).
IL36RN is primarily expressed in the skin (Mulero et al.,
1999) and is an antagonist of three cytokines that belong to the
interleukin-1 family: interleukin-36a (IL36A), interleukin-36b,
and interleukin-36g, which are also known as interleukin-1F6,
interleukin-1F8, and interleukin-1F9, respectively (Kumar
et al., 2000; Smith et al., 2000; Blumberg et al., 2010;
Dinarello et al., 2010). These cytokines activate several pro-
inflammatory signaling pathways, such as the nuclear factor-
kB and mitogen-activated protein kinase pathways (Debets
et al., 2001; Towne et al., 2004). Il1f6 is the mouse ortholog
of IL36A. Abnormal IL-36 receptor signaling results in
transient skin inflammation characterized by acanthosis,
hyperkeratosis, and neutrophil-dominant mixed-cell infiltration
in Il1f6 transgenic mice (Blumberg et al., 2007), which
resembles human GPP as well as PV. Il1f5 is the mouse
ortholog of IL36RN. When the Il1f6 transgenic mice are
crossed with Il1f5-knockout mice, the skin phenotype is
more similar to human GPP than that of the Il1f6 transgenic
mice (Blumberg et al., 2007). These findings strongly suggest
that IL36RN deficiency is associated with the pathogenesis
of GPP.
This study aims to determine the prevalence of IL36RN
mutations in Japanese GPP patients and to evaluate IL36RN
mutations as a causative or predisposing factor for GPP.
Eleven cases of GPP without PV (GPP alone) and 20 cases
of GPP accompanied by PV (GPP with PV) were analyzed.
RESULTS
Clinical features of the patients: GPP patients subdivide into GPP
alone and GPP with PV
This study consisted of 31 Japanese patients with GPP who
were mostly unrelated except for three pairs of siblings
including one monozygotic twins (Table 1). Four patients,
Patients 1, 6, 10, and 11, had consanguineous parents,
including the case we previously reported as the first case of
GPP with IL36RN mutations in Asia (Sugiura et al., 2012).
There was no consanguinity in the families of the other
patients. All 31 of the GPP patients repeatedly exhibited
fresh erythema and pustules on the whole body,
accompanied by high fever, high C-reactive protein, and
neutrophilia, and skin biopsy showed spongiform pustules
of Kogoj in the subcorneal portion of the epidermis. The
GPP cases were classified into two groups: GPP without PV,
designated as ‘‘GPP alone’’, and GPP accompanied by PV,
designated as ‘‘GPP with PV’’ (Figure 1). The detailed clinical
information, including the age at onset of GPP and whether it
was preceded or accompanied by PV, is summarized in
Table 1.
Nine out of 11 GPP alone patients had homozygous or
compound heterozygous IL36RN mutations
Direct sequencing analysis of exons and intron–exon bound-
aries of IL36RN revealed that GPP alone Patients 1, 5, 6, 7,
and 9 were homozygous for c.28C4T (p.Arg10X) (Table 1).
GPP alone Patients 2, 3, 4, and 8, and a pair of siblings with
GPP with PV, Patients 24 and 25, were compound hetero-
zygous for the two mutations c.28C4T (p.Arg10X) and
c.115þ6T4C (Figure 2a and b). A GPP with PV patient,
Patient 29, was heterozygous c.28C4T (p.Arg10X). There was
a significant difference in the frequencies of IL36RN mutations
between GPP and GPP with PV: 9 out of 11 vs. 3 out of 20
(Po0.01). All the parents of the patients with homozygous or
compound heterozygous IL36RN mutations whose DNA was
available for mutation search were heterozygous carriers
of one of the two mutations (data not shown). These two
mutations were not found in 200 normal unrelated alleles
(100 healthy Japanese individuals) by direct sequence analysis
(data not shown). No other pathogenic mutations were found
in the entire exon or at the intron/exon borders of the IL36RN
gene in any patient.
Verification of IL36RN aberrant splicing by mRNA analysis using
plucked hairs
We confirmed that IL36RN messenger RNA (mRNA)
expressed by cutaneous epithelial cells can be obtained in
total RNA extracted from plucked hairs in normal control
individuals by using quantitative PCR (data not shown). Then,
we examined whether the IL36RN mutation c.115þ6T4C
leads to aberrant or normal splicing, because the mutation
c.115þ6T4C is at the splice donor site. PCR analysis showed
a larger amount of aberrantly spliced mRNA products than
normally spliced products in total RNA samples from the
patients’ plucked hair (Figure 2c). The sequencing of com-
plementary DNA (cDNA) fragments from exon 2 to exon 4
amplified using cDNAs obtained by reverse transcription of
total RNA extracted from hairs of the patient demonstrated
an IL36RN splice variant showing the skipping of exon 3
(Figure 2d). Thus, it was confirmed that the splice-site
mutation results in the skipping of exon 3 and leads to
premature translation termination, resulting in the truncation
of IL36RN as p. Arg10ArgfsX1 (Figure 2e).
HLA typing on a family of patients with GPP with PV that had
IL36RN compound heterozygous mutations
Patients 24 and 25 were siblings and were compound
heterozygous for the two IL36RN mutations c.28C4T
(p.Arg10X) and c.115þ 6T4C. Both were GPP with PV. In
order to address the reason why they suffer from PV in spite
the fact that they are GPP patients with compound hetero-
zygous mutations of IL36RN, HLA typing was conducted on
the family. Patients 24 and 25 had paternal HLA-A*0206, but
their healthy brother did not have the HLA haplotype
(Figure 3). HLA-A*0206 is a PV-susceptible HLA haplotype
(Muto et al., 1995, 1996). Therefore, we considered HLA-
A*0206 might contribute to the pathogenesis of PV in Patients
24 and 25.
Haplotype analysis reveals founder effects of IL36RN mutations
in GPP alone patients
The haplotype block structure flanking the IL36RN gene was
constructed using genotype data from the HapMap database
(Figure 4). The haplotype block was represented by four
haplotypes with 41% frequency (Figure 4). The IL36RN
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mutation c.28C4T (p.Arg10X) was found in 12 GPP patients
(Table 1). In all the patients, the chromosome containing the
IL36RN mutation c.28C4T had an identical haplotype,
haplotype II (ATTACATT), which is seen in 21.5% of the
Japanese population. We found the IL36RN mutation
c.115þ6T4C in six GPP patients (Table 1). In all the patients,
the chromosome containing the IL36RN mutation
c.115þ6T4C had an identical, very rare haplotype (ACTA-
CACC), which is seen in o1% of the Japanese population.
Thus, the mutations c.28C4T (p.Arg10X) and c.115þ6T4C
in the present Japanese GPP patients appear to represent
founder effects of the two prevalent mutant IL36RN alleles
among GPP patients in this island nation.
Almost no expression of IL36RN in the epidermis of GPP alone
patients with IL36RN mutations
Immunohistochemical staining with goat polyclonal anti-
IL36RN antibody was conducted with the skin specimen from
three GPP alone patients who had compound heterozygous
IL36RN mutations c.28C4T (p.Arg10X) and c.115þ6T4C
(p. Arg10ArgfsX1), and with that of six GPP with PV patients
who had no IL36RN mutation. Strong IL36RN expression was
seen in the upper spinous and granular layers of the epidermis
of a patient with PV as the positive control (Figure 5). Almost
no expression of IL36RN was observed in the epidermis of
the GPP alone patients with IL36RN mutations, but strong
expression was seen in the granular layers of the epidermis
Table 1. Summary of the GPP patients analyzed in this study
Patient Group
Preceeding or
accompanied
by PV Gender Age of onset Consanguity
Family
history IL36RN mutation
1 GPP alone  M 34 þ  c.28C4T homo
2 GPP alone  M 2  þ c.28C4T hetero, c.115þ 6T4C hetero
3 GPP alone  M 2  þ c.28C4T hetero, c.115þ 6T4C hetero
4 GPP alone  F 5   c.28C4T hetero, c.115þ 6T4C hetero
5 GPP alone  F 65   c.28C4T homo
6 GPP alone  F 40 þ  c.28C4T homo
7 GPP alone  F 21   c.28C4T homo
8 GPP alone  M 6   c.28C4T hetero, c.115þ 6T4C hetero
9 GPP alone  M 8  þ c.28C4T homo
10 GPP alone  M 7 þ þ 
11 GPP alone  M 2 þ þ 
12 GPP with PV þ F 9   
13 GPP with PV þ F 15   
14 GPP with PV þ F 75   
15 GPP with PV þ F 58   
16 GPP with PV þ M 45   
17 GPP with PV þ F 32   
18 GPP with PV þ F 27   
19 GPP with PV þ M 22   
20 GPP with PV þ M 59   
21 GPP with PV þ F 72   
22 GPP with PV þ M 28   
23 GPP with PV þ M 20   
24 GPP with PV þ M 24  þ c.28C4T hetero, c.115þ 6T4C hetero
25 GPP with PV þ F 20  þ c.28C4T hetero, c.115þ 6T4C hetero
26 GPP with PV þ F 42   
27 GPP with PV þ M 59   
28 GPP with PV þ M 78   
29 GPP with PV þ M 50   c.28C4T hetero
30 GPP with PV þ M 24  þ 
31 GPP with PV þ M 38   
Abbreviations: F, female; GPP, generalized pustular psoriasis; M, male; PV, psoriasis vulgaris.
Patients 2 and 3 are monozygotic twins; Patients 10 and 11, and Patients 24 and 25 are sibling pairs.
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of the patients with GPP with PV. Thus, it was apparent that
the IL36RN protein was mostly absent in the patient with GPP
alone owing to IL36RN mutations. The result was the same as
the findings seen in the skin specimen of the patient with GPP
alone who had a homozygous mutation of c.28C4T
(p.Arg10X) as reported previously (Sugiura et al., 2012).
DISCUSSION
Recently, Marrakchi et al. (2011) reported a homozygous
missense mutation p.Leu27Pro in IL36RN as underlying
autosomal recessive GPP in nine Tunisian families. Barker
group identified IL36RN mutations in three out of five patients
with GPP alone using an exome-sequencing strategy
(Onoufriadis et al., 2011). In the report, they mentioned,
without showing any data, that they did not find any IL36RN
mutations in a cohort of 30 individuals with a range of
pustular forms of psoriasis, including GPP with preexisting
PV or palmo-plantar pustulosis. Thus, they suggested that
mutation of IL36RN might be specific to a subtype of GPP not
associated with palmo-plantar pustulosis or PV. However, the
same group very recently reported that four Asian patients
with GPP associated with PV and two European patients with
palmo-plantar pustulosis associated with PV had homozygous
or compound heterozygous mutations in IL36RN (Setta-
Kaffetzi et al., 2013). In addition, two reports were
published on the prevalence of IL36RN mutations in GPP
from China and Japan (Farooq et al., 2013; Li et al. 2013). Li
et al. analyzed mutations of IL36RN in nine cases with GPP
alone, and one case with GPP with PV in the Chinese
population, and they found no IL36RN mutation at all (Li
et al. 2013). In addition, Farooq et al. (2013) found IL36RN
compound heterozygous mutations only in one patient out of
nine cases with GPP alone, and also in one case out of five
patients with GPP with PV in the Japanese population. In light
of this, the prevalence of IL36RN mutations in GPP patients
and the specificity of IL36RN mutations to the subtypes of GPP
are highly controversial.
In this study, we determined that the majority of GPP alone
patients had homozygous or compound heterozygous muta-
tions in IL36RN. In contrast, only a small number of patients
with GPP with PV had IL36RN mutations. Immunohistochem-
ical staining for IL36RN revealed almost no expression of
IL36RN in the skin lesions of Japanese GPP alone patients with
IL36RN mutations, although IL36RN staining was observed in
the skin lesions of GPP with PV patients who had no IL36RN
mutation. These facts clearly demonstrate that GPP alone is a
distinct subtype of GPP, as distinguished from GPP with PV,
and that all or at least the majority of GPP alone patients have
DITRA owing to homozygous or compound heterozygous
mutations of IL36RN.
The results of above-mentioned reports by Li et al. (2013)
and Farooq et al. (2013) on frequencies of IL36RN mutations
in GPP alone are quite different from the results we have
presented here, although the frequency of IL36RN mutations
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Figure 1. Representative clinical features of the two subtypes of generalized pustular psoriasis (GPP): GPP alone and GPP with psoriasis vulgaris (PV). (a, b) GPP
alone patient (Patient 2). Pustules on background erythema are seen on the trunk. (c–e) GPP with PV patient (Patient 12). Both pustular lesions (c, d) and psoriatic
plaques (e) are observed on the trunk at different times.
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in GPP with PV in the report by Farooq et al. agrees with our
results. We do not know the exact reason for the discrepancy,
but it may be owing to the difficulty of classifying GPP patients
precisely into the two groups. GPP patients sometimes have a
long disease history, and it is very difficult to clarify the entire
disease history completely and to precisely evaluate whether
GPP patients have preceding PV lesions. Despite GPP being
an extremely rare disorder, the present study collected a
relatively large number of GPP patients. In addition, we
carefully and strictly surveyed patient histories in making
the classification of GPP alone versus GPP with PV. We
comprehensively researched the entire history of the GPP
patients included in the present study, even in the cases whose
disease history was longer than decades, and we revealed the
presence or absence of PV precisely in all the patients. This
strict classification leads to the present determination that GPP
alone is a distinct subtype of GPP due to IL36RN mutations.
We also presented data that strongly suggest the two
mutations of p.Arg10X (c.28C4T) and p.Arg10ArgfsX1
(c.115þ 6T4C) are founder mutations in the Japanese popu-
lation, by using haplotype analysis. The mutation of p.Arg10X
(c.28C4T) was reported by us and that of Arg10ArgfsX1
(c.115þ 6T4C) was reported by Farooq et al. recently in
Japanese patients with GPP (Sugiura et al., 2012; Farooq et al.,
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Figure 2. Mutation analysis of IL36RN and analysis of IL36RN messenger RNA (mRNA) from plucked hair samples. (a–c) Representative sequencing data
of the patients and controls. (a) Direct sequencing reveals a heterozygous c.28C4T mutation in Patient 2 and homozygous c.28C4T mutations in Patient 5 in
exon 2. (b) Direct sequencing reveals a heterozygous c.115þ 6 T4C mutation in Patient 2 in intron 3–4. (c) In Patient 2, who is compound heterozygous for
c.28C4T and c.115þ6 T4C, normal transcripts and aberrantly spliced, shorter transcripts are identified by reverse transcriptase–PCR (RT–PCR) of IL36RN
exon 2–exon 4 mRNA fragments. (d) Direct sequencing of the RT–PCR products shorter than those of normal controls revealed that the aberrant splicing resulted in
the skipping of exon 3 in the patient’s IL36RN mRNA. Direct sequencing of RT–PCR products longer than those of normal controls revealed unrelated DNA
sequence (data not shown). (e) Second structures of wild-type IL36RN and the mutant IL36RN produced from the mutant alleles. Note the mutant products have
no critical residues that mediate the receptor interaction, such as His32, Lys38, Tyr89, Glu94, and Lys96 of IL36RN (Farooq et al., 2013).
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Figure 3. HLA-A typing and mutation analysis of IL36RN in the family of
Patients 24 and 25. HLA-A typing and mutation analysis of IL36RN in the
family of Patients 24 and 25. Both patients with generalized pustular psoriasis
with psoriasis vulgaris (PV) have the PV-susceptible HLA haplotype HLA-
A*0206 as well as the two IL36RN mutations.
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Figure 4. The linkage disequilibrium (LD) block and the haplotype structure around IL36RN in ethnic Japanese populations. IL36RN structure and the LD block
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Figure 5. Representative photos of histopathology of the generalized pustular psoriasis (GPP) skin lesions and distribution of interleukin-36 receptor antagonist
(IL36RN). (a–c) (a) Histopathological features of pustular lesions in patients with GPP alone (Patient 4 with IL36RN mutations) and (b) GPP with psoriasis
vulgaris (PV) (Patient 12 without any IL36RN mutation) and (c) a typical psoriatic plaque. Characteristic features of psoriasis, acanthosis, hyperkeratosis, and
parakeratosis are seen in the epidermis of all the lesions. Pustules are observed in the epidermis of pustular lesions in both (a) the GPP alone patient and (b) the GPP
with PV patient. Hematoxylin (HE) and eosin stain; bar¼ 50mm. (d–f) (d) Immunohistochemical staining for IL36RN in the pustular lesions of GPP patients,
a GPP alone patient with IL36RN mutations (Patient 4), and (e) GPP with PV patient not carrying any IL36RN mutations (Patient 12), and (f) in a psoriatic plaque as
positive control. No IL36RN staining is seen in any part of the epidermis in the GPP alone patient carrying IL36RN mutations, although strong IL36RN labeling is
observed in the upper epidermis of the pustular lesion of the GPP with PV patient without any IL36RN mutations and of a typical psoriatic lesion as a positive
control. Anti-IL1F5 (IL36RN) antibody stain, bar¼ 50mm.
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2013). Considering that the majority of Japanese GPP patients
with GPP alone who were from genetically independent
families were homozygous or compound heterozygous for
these two mutations, these two IL36RN mutations are sug-
gested to be founder mutations in the Japanese population.
Haplotype analysis in the present study confirmed that the two
mutations are strong founder mutations causing GPP alone in
the Japanese population.
Concerning the fact that Li et al. (2013) found no IL36RN
mutations in nine Chinese patients with GPP alone, we cannot
completely exclude the possibility that there might be no
founder with IL36RN mutations and that molecules other than
IL36RN could be a cause of GPP alone in China or elsewhere
in the world. However, Marrakchi et al. (2011) analyzed
IL36RN mutations in 19 Tunisian patients with GPP alone
(mostly familial GPP; 18 of the 19 patients were children of
consangunious parents) and the authors found the founder
mutation p.Leu27Pro as a homozygous mutation in all the
patients. In light of this, their findings agree with our finding that
the majority of GPP alone is caused by deficiency of IL36RN.
We also found compound heterozygous mutations of
IL36RN in a pair of siblings with GPP with PV, who had the
PV-susceptible HLA haplotype HLA-A*0206. In the present
series of patients, this family is the only one in which GPP
with PV patients had autosomal recessive IL36RN mutations.
We speculate that, in this family, it is the PV-susceptible HLA
haplotype HLA-A*0206 and not the autosomal recessive
IL36RN mutations that might contribute to the pathogenesis
of additional PV lesions. Most GPP alone cases had IL36RN
mutations, although almost all GPP with PV cases had no
IL36RN mutation. Patients 24 and 25 were exceptional cases
as GPP with PV, because they had IL36RN mutations. Thus, in
Patients 24 and 25, to determine why these two patients had
PV lesions, we conducted HLA typing and found that they had
HLA-A*206, which is responsible for PV. Concerning the
other GPP patients, HLA typing was not conducted in the
present study.
In addition, Patient 29, who had been suffering from GPP
with PV, was heterozygous for p.Arg10X (c.28C4T) in IL36RN.
Three out of the 20 GPP with PV patients had heterozygous or
compound heterozygous mutations of IL36RN. In contrast, no
apparent pathogenic IL36RN mutation was found in 100 healthy
controls. Therefore, we speculate that heterozygous mutation
of IL36RN may be a predisposing factor of GPP with PV.
We successfully performed IL36RN mRNA analysis using
total RNA extracted from plucked hairs, without doing
invasive skin biopsies. The method gave us important informa-
tion on the consequence of the exon–intron boundary site
mutation c.115þ 6T4C. We recently suggested that the mRNA
of genes predominantly expressed in cutaneous epithelial cells
can be analyzed using total RNA extracted from plucked hairs
(Takeichi et al. 2013). This study reinforced the usefulness of
the method. We recommend this method for analyzing the
mRNA of genes predominantly expressed in cutaneous
epithelial cells, because it is less invasive than skin biopsy.
Acute generalized exanthematous pustulosis (AGEP) is
another skin disorder showing generalized pustulosis that is
similar to GPP. The pustulosis is non-episodic in AGEP,
although it is episodic in GPP. However, at the first episode
of generalized pustulosis, it is sometimes difficult to make a
differential diagnosis of AGEP and sporadic cases with GPP
alone. We performed IL36RN mutation search in two cases of
AGEP and found no IL36RN mutation (data not shown). From
this result, we conclude that IL36RN mutation search may be
useful toward making a differential diagnosis of these two
disorders: AGEP and sporadic GPP alone.
Whether GPP alone and GPP with PV are on a spectrum of
identical diseases or are distinct subtypes caused by different
pathogenesis has long been a very important but unanswered
question. The present study clearly demonstrates for the first
time, to our knowledge, that the majority of GPP alone cases
have IL36RN mutations, but most cases of GPP with PV have
no IL36RN mutation. Based on this information, GPP alone is
regarded as a distinct subtype of GPP that is etiologically
different from the other subtype of GPP: GPP with PV. In this
context, we are afraid it may be confusing to use the identical
term ‘‘GPP’’ for both GPP alone resulting from IL36RN
mutations and a syndrome of severe PV with pustular erup-
tions (GPP with PV). Thus, we suggest that it is more
appropriate to use the term ‘‘GPP’’ only for the distinct clinical
entity of GPP alone resulting from IL36RN mutations, but not
for a syndrome of severe PV with pustular eruptions (GPP with
PV). We expect promising new drugs targeting the interleukin-
36 receptor signal in the epidermis for patients with GPP alone
in the near future.
MATERIALS AND METHODS
Subjects
Eleven cases of GPP without PV (GPP alone) including a pair of
monozygotic twins and another pair of siblings, and 20 cases of GPP
accompanied by PV (GPP with PV) including a pair of siblings were
analyzed (Table 1). All the 31 cases are Japanese. One of the GPP
alone cases is the GPP patient with IL36RN mutations whom we
reported previously (Sugiura et al., 2012). The medical ethics
committee of Nagoya University Graduate School of Medicine
approved all the described studies. All the studies were conducted
according to the Declaration of Helsinki Principles. The participants
gave written informed consent.
Mutation detection
IL36RN mutation search was performed as previously reported (Sugiura
et al., 2012). Briefly, genomic DNA isolated from peripheral blood was
subjected to PCR amplification, followed by direct automated
sequencing using an ABI PRISM 3100 genetic analyzer (Advanced
Biotechnologies, Columbia, MD). Oligonucleotide primers were desi-
gned as described previously (Marrakchi et al., 2011). The entire
coding regions of IL36RN including the exon/intron boundaries were
sequenced using genomic DNA samples from patients and their
family members. As normal controls, 100 healthy unrelated Japanese
individuals (200 normal alleles) were studied. The cDNA nucleotides
and the amino acids of the protein were numbered based on the
previous sequence information (GenBank accession No. 26525).
Statistical analysis
Fisher’s exact test was used to compare frequencies of IL36RN
mutations between GPP and GPP with PV.
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mRNA analysis with total RNA extracted from plucked hairs
To analyze IL36RN mRNA, we used plucked hairs from the patients
and normal control individuals using the methods previously
described (Takeichi et al., 2013). In detail, five hairs with roots per
person were obtained from the scalp of the patients and normal
control individuals. Total RNA was extracted from the hair roots using
the RNeasy extraction kit (Qiagen, Hilden, Germany), and cDNAs
were obtained by reverse transcription reverse transcriptase–PCR using
the total RNA. Then, we examined whether c.115þ 6T4C mutation
leads to aberrant or normal splicing using the cDNAs from hairs of the
patient, because the c.115þ 6T4C mutation is at the splice donor
site. The primers are described in Supplementary Table S1 online.
Serological HLA typing and DNA typing of HLA-A2 alleles
HLA typing was done by the standard microcytotoxicity test as
previously described (Muto et al., 1995). Identification of alleles of
HLA-A2 was done by PCR sequence–specific oligonucleotide probes,
as described previously (Date et al., 1996).
Haplotype analysis
To determine whether the mutations c.28C4T (p.Arg10X) and
c.115þ 6T4C are founder mutations, we performed haplotype
analysis. We constructed linkage disequilibrium blocks containing
the IL36RN gene using genotype data from the HapMap database
(HapMap Data Rel 28 PhaseIIþ III). The haplotype structure with its
tag-single-nucleotide polymorphisms was determined using Haplo-
view (Barrett et al., 2005). We genotyped eight tag-single-nucleotide
polymorphisms using the ABI PRISM 3100 genetic analyzer
(Advanced Biotechnologies). The primers are described in
Supplementary Table S1 online.
Immunohistochemistry on skin specimens
Immunohistochemistry on human skin samples was performed as
described previously (Sugiura et al., 2009) with slight modifications.
The Vectastain Elite ABC-PO (goat IgG) kit (Vector Laboratories,
Burlingame, CA) was used for staining. Thin sections (6mm) were cut
from samples embedded in paraffin blocks. Polyclonal goat anti-
IL1F5(IL36RN) antibodies (catalog number: AF1275: R&D Systems,
Minneapolis, MN) (2 ng ml 1) were used as first antibodies.
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